NCT06539793 Effect of Neuromodulation on Pain Biomarkers and Functional Outcome in Patients With Fibromyalgia Syndrome
| NCT ID | NCT06539793 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ahmed Alshimy |
| Condition | Fibromyalgia Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2025-04-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-09-01 with a primary completion date of 2025-04-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Fibromyalgia is the third most common musculoskeletal condition in terms of prevalence, after lumbar pain and osteoarthritis. Its prevalence is around 2-4 % and is more frequent in women than in men; the prevalence is highest in age the range of 40-60 years.
Eligibility Criteria
Inclusion Criteria: 1. Patients fibromyalgia from both genders. 2. The duration of fibromyalgia is more than 6 month (all patients with history of cervical or lumbar pain) and following diagnosis of FM using the 2016 revised FM criteria, on the basis of the ACR-2010 criteria. 3. Their ages will be ranged from 25-35 years old. 4. They will be medically stable and have sufficient cognitive abilities that enable them to understand and follow instruction according to Montreal Cognitive Assessment (MoCA) \>26. Exclusion Criteria: 1. Other Neurological diseases as stroke , multiple sclerosis, Parkinson's disease and motor neuron disease 2. Pacemaker 3. Spinal fusion-cervical or lumbar 4. Metal implants in the spine 5. Pregnancy 6. Epilepsy 7. Severe psychiatric disorder or alcohol and drug abuse. 8. Unstable medical condition which could compromise the participant's welfare or confound the study results. 9. Uncontrolled blood pressure or diabetes 10. Visual or auditory problems. 11. Active inflammatory conditions
Frequently Asked Questions
Who can join the NCT06539793 clinical trial?
This trial is open to participants of all sexes, aged 25 Years or older, up to 35 Years, studying Fibromyalgia Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06539793 currently recruiting?
Yes, NCT06539793 is actively recruiting participants. Visit ClinicalTrials.gov or contact Ahmed Alshimy to inquire about joining.
Where is the NCT06539793 trial being conducted?
This trial is being conducted at Sadat, Egypt.
Who is sponsoring the NCT06539793 clinical trial?
NCT06539793 is sponsored by Ahmed Alshimy. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.